Literature DB >> 20694523

The novel role of fenofibrate in preventing nicotine- and sodium arsenite-induced vascular endothelial dysfunction in the rat.

Jagdeep Kaur1, Krishna Reddy, Pitchai Balakumar.   

Abstract

The present study investigated the effect of fenofibrate, an agonist of PPAR-alpha, in nicotine- and sodium arsenite-induced vascular endothelial dysfunction (VED) in rats. Nicotine (2 mg/kg/day, i.p., 4 weeks) and sodium arsenite (1.5 mg/kg/day, i.p., 2 weeks) were administered to produce VED in rats. The scanning electron microscopy study in thoracic aorta revealed that administration of nicotine or sodium arsenite impaired the integrity of vascular endothelium. Further, administration of nicotine or sodium arsenite significantly decreased serum and aortic concentrations of nitrite/nitrate and subsequently reduced acetylcholine-induced endothelium-dependent relaxation. Moreover, nicotine or sodium arsenite produced oxidative stress by increasing serum thiobarbituric acid reactive substances (TBARS) and aortic superoxide generation. However, treatment with fenofibrate (30 mg/kg/day, p.o.) or atorvastatin (30 mg/kg/day p.o., a standard agent) significantly prevented nicotine- and sodium arsenite-induced VED and oxidative stress by improving the integrity of vascular endothelium, increasing the concentrations of serum and aortic nitrite/nitrate, enhancing the acetylcholine-induced endothelium-dependent relaxation and decreasing serum TBARS and aortic superoxide anion generation. Conversely, co-administration of L-NAME (25 mg/kg/day, i.p.), an inhibitor of nitric oxide synthase, markedly attenuated these vascular protective effects of fenofibrate. The administration of nicotine or sodium arsenite altered the lipid profile by increasing serum cholesterol and triglycerides and consequently decreasing high-density lipoprotein levels, which were significantly prevented by treatment with fenofibrate or atorvastatin. It may be concluded that fenofibrate improves the integrity and function of vascular endothelium, and the vascular protecting potential of fenofibrate in preventing the development of nicotine- and sodium arsenite-induced VED may be attributed to its additional properties (other than lipid lowering effect) such as activation of eNOS and generation of NO and consequent reduction in oxidative stress.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20694523     DOI: 10.1007/s12012-010-9086-7

Source DB:  PubMed          Journal:  Cardiovasc Toxicol        ISSN: 1530-7905            Impact factor:   3.231


  5 in total

Review 1.  Submaximal PPARγ activation and endothelial dysfunction: new perspectives for the management of cardiovascular disorders.

Authors:  Pitchai Balakumar; Sonam Kathuria
Journal:  Br J Pharmacol       Date:  2012-08       Impact factor: 8.739

Review 2.  Interplay between statins and PPARs in improving cardiovascular outcomes: a double-edged sword?

Authors:  Pitchai Balakumar; Nanjaian Mahadevan
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

3.  Unraveling mechanisms of toxicant-induced oxidative stress in cardiovascular disease.

Authors:  Tammy R Dugas
Journal:  Curr Opin Toxicol       Date:  2017-10-12

4.  Possible involvement of PPARγ-associated eNOS signaling activation in rosuvastatin-mediated prevention of nicotine-induced experimental vascular endothelial abnormalities.

Authors:  Sonam Kathuria; Nanjaian Mahadevan; Pitchai Balakumar
Journal:  Mol Cell Biochem       Date:  2012-11-10       Impact factor: 3.396

Review 5.  Modulation of Hypercholesterolemia-Induced Oxidative/Nitrative Stress in the Heart.

Authors:  Csaba Csonka; Márta Sárközy; Márton Pipicz; László Dux; Tamás Csont
Journal:  Oxid Med Cell Longev       Date:  2015-12-14       Impact factor: 6.543

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.